4//SEC Filing
HURWITZ EDWARD 4
Accession 0001209191-12-049852
CIK 0001338042other
Filed
Oct 16, 8:00 PM ET
Accepted
Oct 17, 6:35 PM ET
Size
26.8 KB
Accession
0001209191-12-049852
Insider Transaction Report
Form 4
ALTA BIOPHARMA PARTNERS III LP
10% Owner
Transactions
- Sale
Common Stock
2012-10-15$17.54/sh−55,626$975,680→ 2,408,426 total - Sale
Common Stock
2012-10-15$17.54/sh−3,736$65,529→ 161,742 total(indirect: See footnote) - Sale
Common Stock
2012-10-16$18.67/sh−128,229$2,394,035→ 2,280,197 total - Sale
Common Stock
2012-10-16$18.67/sh−8,611$160,767→ 153,131 total(indirect: See footnote) - Sale
Common Stock
2012-10-16$18.67/sh−3,160$58,997→ 56,190 total(indirect: See footnote) - Sale
Common Stock
2012-10-15$17.54/sh−1,371$24,047→ 59,350 total(indirect: See footnote)
CHAMPSI FARAH
10% Owner
Transactions
- Sale
Common Stock
2012-10-16$18.67/sh−128,229$2,394,035→ 2,280,197 total - Sale
Common Stock
2012-10-15$17.54/sh−3,736$65,529→ 161,742 total(indirect: See footnote) - Sale
Common Stock
2012-10-15$17.54/sh−55,626$975,680→ 2,408,426 total - Sale
Common Stock
2012-10-15$17.54/sh−1,371$24,047→ 59,350 total(indirect: See footnote) - Sale
Common Stock
2012-10-16$18.67/sh−8,611$160,767→ 153,131 total(indirect: See footnote) - Sale
Common Stock
2012-10-16$18.67/sh−3,160$58,997→ 56,190 total(indirect: See footnote)
HURWITZ EDWARD
10% Owner
Transactions
- Sale
Common Stock
2012-10-15$17.54/sh−55,626$975,680→ 2,408,426 total - Sale
Common Stock
2012-10-16$18.67/sh−8,611$160,767→ 153,131 total(indirect: See footnote) - Sale
Common Stock
2012-10-16$18.67/sh−128,229$2,394,035→ 2,280,197 total - Sale
Common Stock
2012-10-16$18.67/sh−3,160$58,997→ 56,190 total(indirect: See footnote) - Sale
Common Stock
2012-10-15$17.54/sh−3,736$65,529→ 161,742 total(indirect: See footnote) - Sale
Common Stock
2012-10-15$17.54/sh−1,371$24,047→ 59,350 total(indirect: See footnote)
Transactions
- Sale
Common Stock
2012-10-15$17.54/sh−55,626$975,680→ 2,408,426 total - Sale
Common Stock
2012-10-15$17.54/sh−1,371$24,047→ 59,350 total(indirect: See footnote) - Sale
Common Stock
2012-10-16$18.67/sh−8,611$160,767→ 153,131 total(indirect: See footnote) - Sale
Common Stock
2012-10-16$18.67/sh−3,160$58,997→ 56,190 total(indirect: See footnote) - Sale
Common Stock
2012-10-16$18.67/sh−128,229$2,394,035→ 2,280,197 total - Sale
Common Stock
2012-10-15$17.54/sh−3,736$65,529→ 161,742 total(indirect: See footnote)
PENHOET EDWARD
10% Owner
Transactions
- Sale
Common Stock
2012-10-15$17.54/sh−55,626$975,680→ 2,408,426 total - Sale
Common Stock
2012-10-16$18.67/sh−8,611$160,767→ 153,131 total(indirect: See footnote) - Sale
Common Stock
2012-10-16$18.67/sh−128,229$2,394,035→ 2,280,197 total - Sale
Common Stock
2012-10-15$17.54/sh−3,736$65,529→ 161,742 total(indirect: See footnote) - Sale
Common Stock
2012-10-15$17.54/sh−1,371$24,047→ 59,350 total(indirect: See footnote) - Sale
Common Stock
2012-10-16$18.67/sh−3,160$58,997→ 56,190 total(indirect: See footnote)
ALTA BIOPHARMA MANAGEMENT III LLC
10% Owner
Transactions
- Sale
Common Stock
2012-10-16$18.67/sh−128,229$2,394,035→ 2,280,197 total - Sale
Common Stock
2012-10-15$17.54/sh−55,626$975,680→ 2,408,426 total - Sale
Common Stock
2012-10-16$18.67/sh−8,611$160,767→ 153,131 total(indirect: See footnote) - Sale
Common Stock
2012-10-16$18.67/sh−3,160$58,997→ 56,190 total(indirect: See footnote) - Sale
Common Stock
2012-10-15$17.54/sh−3,736$65,529→ 161,742 total(indirect: See footnote) - Sale
Common Stock
2012-10-15$17.54/sh−1,371$24,047→ 59,350 total(indirect: See footnote)
Transactions
- Sale
Common Stock
2012-10-15$17.54/sh−55,626$975,680→ 2,408,426 total - Sale
Common Stock
2012-10-16$18.67/sh−128,229$2,394,035→ 2,280,197 total - Sale
Common Stock
2012-10-16$18.67/sh−8,611$160,767→ 153,131 total(indirect: See footnote) - Sale
Common Stock
2012-10-15$17.54/sh−3,736$65,529→ 161,742 total(indirect: See footnote) - Sale
Common Stock
2012-10-15$17.54/sh−1,371$24,047→ 59,350 total(indirect: See footnote) - Sale
Common Stock
2012-10-16$18.67/sh−3,160$58,997→ 56,190 total(indirect: See footnote)
Kiley Alison
Director10% Owner
Transactions
- Sale
Common Stock
2012-10-15$17.54/sh−55,626$975,680→ 2,408,426 total - Sale
Common Stock
2012-10-16$18.67/sh−128,229$2,394,035→ 2,280,197 total - Sale
Common Stock
2012-10-16$18.67/sh−8,611$160,767→ 153,131 total(indirect: See footnote) - Sale
Common Stock
2012-10-15$17.54/sh−3,736$65,529→ 161,742 total(indirect: See footnote) - Sale
Common Stock
2012-10-16$18.67/sh−3,160$58,997→ 56,190 total(indirect: See footnote) - Sale
Common Stock
2012-10-15$17.54/sh−1,371$24,047→ 59,350 total(indirect: See footnote)
Footnotes (6)
- [F1]On October 15, 2012, Alta BioPharma Partners III, L.P. ("ABPIII"), Alta BioPharma Partners III GmbH & Co. Beteiligungs KG ("ABMPIIIKG"), and Alta Embarcadero BioPharma Partners III, LLC ("AEBPIII") disposed of 55,626, 3,736 and 1,371 shares of the Issuer's Common Stock, respectively, on the public market at an average price of $17.54 per share. The range of sale prices for the transactions reported was $17.20 to $18.08 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- [F2]These securities are beneficially owned by ABPIII.
- [F3]Alta BioPharma Management III, LLC ("ABMIII") is the general Partner of ABPIII, the managing limited partner of ABPIIIKG. Farah Champsi, Edward Penhoet, and Edward Hurwitz are directors of ABMIII and managers of AEBPIII, along with ABPIII and ABPIIIKG shall be known as "the Funds," exercise shared voting and investment power with respect to the securities held by the Funds. Alison Kiley is a member of ABM III. Each of the reporting persons disclaim beneficial ownership of such securities, except to the extend of his, her, or its proportionate pecuniary interest herein.
- [F4]On October 16, 2012, ABPIII, ABMPIIIKG, and AEBPIII disposed of 128,229, 8,611 and 3,160 shares of the Issuer's Common Stock, respectively, on the public market at an average price of $18.67 per share. The range of sale prices for the transactions reported was $18.20 to $19.23 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- [F5]These securities are beneficially owned by ABPIIIKG.
- [F6]These securities are beneficially owned by AEBPIII.
Documents
Issuer
Aegerion Pharmaceuticals, Inc.
CIK 0001338042
Entity typeother
Related Parties
1- filerCIK 0001211840
Filing Metadata
- Form type
- 4
- Filed
- Oct 16, 8:00 PM ET
- Accepted
- Oct 17, 6:35 PM ET
- Size
- 26.8 KB